ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced financial results for the third quarter ended September 30, 2023.
Third Quarter and Recent Highlights
- Total revenue of $8.0 million in the third quarter of 2023, a decrease of 25% compared to the third quarter of 2022.
- Core business revenue of $6.6 million in the third quarter of 2023, a decrease of 33% compared to the third quarter of 2022.
- SPL Program-related revenue of $1.4 million in the third quarter of 2023, compared to $0.8 million in the third quarter of 2022.
- Gross profit of $7.2 million (90% gross margin), compared to $9.3 million (87% gross margin) in the third quarter of 2022.
- Full year 2023 revenue guidance of approximately $34-$36 million total revenue and approximately $28-$30 million of core revenue, and SPL Program-related revenue of approximately $6 million, all consistent with guidance previously provided on October 4th.
- Total cash, cash equivalents and investments were $208.7 million as of September 30, 2023.
- We continue to expect to end the year with approximately $200 million in cash, cash equivalents and investments, which would be unchanged from our initial outlook at the beginning of the year.
“MaxCyte’s third quarter revenue was at the higher end of our preliminary revenue range we announced in October. We continue to evaluate and address the industry challenges we have seen throughout 2023, with performance in-line with the revised guidance that we provided last month. Customers, particularly early-stage customers, continue to reprioritize their spend and operate with more caution—an operating environment we expect to persist at least through the remainder of 2023,” said Doug Doerfler, President and Chief Executive Officer at MaxCyte.
“Despite these challenges, we believe that the long-term opportunity for the cell and gene therapy market is robust and continue to make targeted investments that support the industry and our partners in their development of high-potential complex cell therapies through the clinical and commercial stages. This includes further expansion of gene-editing modalities and indications such as autoimmune disease, solid tumors, and rare diseases. We are proud of our partners’ progress and success thus far and we look forward to cell therapies supported by MaxCyte’s platform entering the market in the near, medium, and long term. Importantly, we remain confident in our ability to expand our partnership portfolio and support the market in enabling a growing set of next-generation cell therapies. We are also excited about the prospects of the VLx platform and expanding our market opportunity into bioprocessing applications including rapid large-scale transiently expressed protein production for preclinical and early clinical use.”
The following table provides details regarding the sources of our revenue for the periods presented.
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||
| 2023 | 2022 | % | 2023 | 2022 | % | ||||||||||||||||
| (in thousands, except percentages) | |||||||||||||||||||||
| Cell therapy | $ | 4,701 | $ | 7,898 | (40 | %) | $ | 17,311 | 23,002 | (25 | %) | ||||||||||
| Drug discovery | 1,900 | 1,991 | (5 | %) | 5,350 | 6,074 | (12 | %) | |||||||||||||
| Program-related | 1,404 | 754 | 86 | % | 2,962 | 2,762 | 7 | % | |||||||||||||
| Total revenue | $ | 8,005 | $ | 10,643 | (25 | %) | $ | 25,623 | $ | 31,838 | (20 | %) | |||||||||
Third Quarter 2023 Financial Results
Total revenue for the third quarter of 2023 was $8.0 million, compared to $10.6 million in the third quarter of 2022, representing a decline of 25%.
Core business revenue (sales and leases of instrument and disposables to cell therapy and drug discovery customers, excluding SPL Program-related revenue) for the third quarter of 2023 was $6.6 million, compared to $9.9 million in the third quarter of 2022, representing a decline of 33%.
Cell therapy revenue for the third quarter of 2023 was $4.7 million, compared to $7.9 million in the third quarter of 2022, representing a decline of 40%. Drug discovery revenue for the third quarter of 2023 was $1.9 million, compared to $2.0 million in the third quarter of 2022, representing a decline of 5%.
Strategic Platform License (SPL) Program-related revenue was $1.4 million in the third quarter of 2023, as compared to $0.8 million in the third quarter of 2022.
Gross profit for the third quarter of 2023 was $7.2 million (90% gross margin), compared to $9.3 million (87% gross margin) in the third quarter of 2022.
Operating expenses for the third quarter of 2023 were $21.2 million, compared to operating expenses of $17.0 million in the third quarter of 2022.
Third quarter 2023 net loss was $11.3 million compared to net loss of $6.4 million for the same period in 2022. EBITDA, a non-GAAP measure, was a loss of $12.9 million for the third quarter of 2023, compared to a loss of $7.1 million for the third quarter of 2022. Stock-based compensation expense was $3.6 million for the third quarter versus $3.2 million for the third quarter of 2022.
2023 Revenue Guidance
- Total revenue expected to be approximately $34 - 36 million for the year.
- Core revenue expected to be approximately $28 - 30 million for the year.
- SPL Program-related revenue expected to be approximately $6 million for the year.
Webcast and Conference Call Details
MaxCyte will host a conference call today, November 8, 2023, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on Twitter and LinkedIn.
Non-GAAP Financial Measures
This press release contains EBITDA, which is a non-GAAP measure defined as earnings, before interest, tax, depreciation and amortization. MaxCyte believes that EBITDA provides useful information to management and investors relating to its results of operations. The company’s management uses this non-GAAP measure to compare the company’s performance to that of prior periods for trend analyses, and for budgeting and planning purposes. The company believes that the use of EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the company’s financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics used by management in its financial and operational decision-making.
Management does not consider EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of EBITDA is that it excludes significant expenses that are required by GAAP to be recorded in the company’s financial statements. In order to compensate for these limitations, management presents EBITDA together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of net loss, the most comparable GAAP financial measure, to EBITDA is included at the end of this release. MaxCyte urges investors to review the reconciliation and not to rely on any single financial measure to evaluate the company’s business.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding expected total revenue, core business revenue and SPL Program-related revenue for the year ending December 31, 2023, cash resources and investments at the end of 2023, reduced spend in the near term from early-stage customers, longer-term growth of the cell therapy industry, expansion of the company’s platform into bioprocessing applications, expansion of and revenue from our SPLs and the progression of our customers’ programs into and through clinical trials and into commercialization. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," “prospect,” "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with the timing and outcome of our customers’ ongoing and planned clinical trials; the adequacy of our cash resources and availability of financing on commercially reasonable terms; general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and market acceptance and demand for our technology and products. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 15, 2023, as well as in discussions of potential risks, uncertainties, and other important factors in our most recent Quarterly report on Form 10-Q and the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements represent our views only as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA | +1 415-937-5400 ir@maxcyte.com | |
| US Media Relations Seismic Valerie Enes Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden | +1 408-497-8568 +44 (0)20 7886 2500 | |
| UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh | +44 (0)203 709 5700 maxcyte@consilium-comms.com | |
MaxCyte, Inc.
Unaudited Consolidated Balance Sheets
| September 30, | December 31, | |||||||
| 2023 | 2022 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 49,170,300 | $ | 11,064,700 | ||||
| Short-term investments, at amortized cost | 141,070,100 | 216,274,900 | ||||||
| Accounts receivable, net | 8,166,700 | 11,654,600 | ||||||
| Accounts receivable – TIA* | — | 1,912,400 | ||||||
| Inventory | 12,532,800 | 8,580,800 | ||||||
| Prepaid expenses and other current assets | 3,399,500 | 2,778,800 | ||||||
| Total current assets | 214,339,400 | 252,266,200 | ||||||
| Investments, non-current, at amortized cost | 18,428,700 | — | ||||||
| Property and equipment, net | 23,771,800 | 23,724,700 | ||||||
| Right-of-use asset - operating leases | 9,567,800 | 9,853,500 | ||||||
| Other assets | 619,400 | 809,000 | ||||||
| Total assets | $ | 266,727,100 | $ | 286,653,400 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 446,600 | $ | 531,800 | ||||
| Accrued expenses and other | 9,917,600 | 8,025,300 | ||||||
| Operating lease liability, current | 698,700 | 156,800 | ||||||
| Deferred revenue, current portion | 5,585,900 | 6,712,600 | ||||||
| Total current liabilities | 16,648,800 | 15,426,500 | ||||||
| Operating lease liability, net of current portion | 15,383,400 | 15,938,100 | ||||||
| Other liabilities | 1,318,400 | 1,321,600 | ||||||
| Total liabilities | 33,350,600 | 32,686,200 | ||||||
| Stockholders’ equity | ||||||||
| Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2023 and December 31, 2022 | — | — | ||||||
| Common stock, $0.01 par value; 400,000,000 shares authorized, 103,548,943 and 102,397,913 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 1,035,500 | 1,024,000 | ||||||
| Additional paid-in capital | 402,861,500 | 390,818,500 | ||||||
| Accumulated deficit | (170,520,500 | ) | (137,875,300 | ) | ||||
| Total stockholders’ equity | 233,376,500 | 253,967,200 | ||||||
| Total liabilities and stockholders’ equity | $ | 266,727,100 | $ | 286,653,400 | ||||
* Tenant improvement allowance (“TIA”)
MaxCyte, Inc.
Unaudited Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue | $ | 8,004,500 | $ | 10,642,800 | $ | 25,623,400 | $ | 31,837,900 | ||||||||
| Cost of goods sold | 793,400 | 1,368,900 | 3,168,900 | 3,551,900 | ||||||||||||
| Gross profit | 7,211,100 | 9,273,900 | 22,454,500 | 28,286,000 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 6,264,100 | 5,325,100 | 17,974,900 | 13,786,400 | ||||||||||||
| Sales and marketing | 7,046,900 | 4,506,700 | 19,779,100 | 13,276,000 | ||||||||||||
| General and administrative | 6,820,300 | 6,444,400 | 21,981,700 | 20,179,600 | ||||||||||||
| Depreciation and amortization | 1,032,500 | 709,800 | 2,922,100 | 1,654,300 | ||||||||||||
| Total operating expenses | 21,163,800 | 16,986,000 | 62,657,800 | 48,896,300 | ||||||||||||
| Operating loss | (13,952,700 | ) | (7,712,100 | ) | (40,203,300 | ) | (20,610,300 | ) | ||||||||
| Other income: | ||||||||||||||||
| Other expense | — | (116,000 | ) | — | (116,000 | ) | ||||||||||
| Interest income | 2,700,900 | 1,394,400 | 7,558,100 | 1,964,900 | ||||||||||||
| Total other income | 2,700,900 | 1,278,400 | 7,558,100 | 1,848,900 | ||||||||||||
| Net loss | $ | (11,251,800 | ) | $ | (6,433,700 | ) | $ | (32,645,200 | ) | $ | (18,761,400 | ) | ||||
| Basic and diluted net loss per share | $ | (0.11 | ) | $ | (0.06 | ) | $ | (0.32 | ) | $ | (0.18 | ) | ||||
| Weighted average shares outstanding, basic and diluted | 103,449,715 | 101,806,173 | 103,121,997 | 101,555,065 | ||||||||||||
MaxCyte, Inc.
Unaudited Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (32,645,200 | ) | $ | (18,761,400 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 3,069,300 | 1,778,300 | ||||||
| Net book value of consigned equipment sold | 80,000 | 61,900 | ||||||
| Loss on disposal of fixed assets | 2,600 | 128,600 | ||||||
| Stock-based compensation | 10,404,500 | 8,633,800 | ||||||
| Bad debt expense | 221,000 | — | ||||||
| Amortization of discounts on investments | (5,123,300 | ) | (1,158,400 | ) | ||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 3,266,900 | (556,800 | ) | |||||
| Accounts receivable - TIA | 1,912,400 | (775,000 | ) | |||||
| Inventory | (4,087,600 | ) | (2,880,700 | ) | ||||
| Prepaid expense and other current assets | (620,700 | ) | 31,800 | |||||
| Right-of-use asset – operating leases | 285,700 | (4,263,000 | ) | |||||
| Other assets | 189,600 | (873,100 | ) | |||||
| Accounts payable, accrued expenses and other | 1,519,800 | 1,156,100 | ||||||
| Operating lease liability | (12,800 | ) | 9,341,900 | |||||
| Deferred revenue | (1,126,700 | ) | (455,000 | ) | ||||
| Other liabilities | (3,200 | ) | (105,600 | ) | ||||
| Net cash used in operating activities | (22,667,700 | ) | (8,696,600 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of investments | (185,620,600 | ) | (213,541,400 | ) | ||||
| Maturities of investments | 247,520,000 | 232,096,000 | ||||||
| Purchases of property and equipment | (2,785,200 | ) | (16,282,600 | ) | ||||
| Proceeds from sale of equipment | 9,100 | — | ||||||
| Net cash provided by investing activities | 59,123,300 | 2,272,000 | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from exercise of stock options | 1,650,000 | 1,662,500 | ||||||
| Net cash provided by financing activities | 1,650,000 | 1,662,500 | ||||||
| Net increase (decrease) in cash and cash equivalents | 38,105,600 | (4,762,100 | ) | |||||
| Cash and cash equivalents, beginning of period | 11,064,700 | 47,782,400 | ||||||
| Cash and cash equivalents, end of period | $ | 49,170,300 | $ | 43,020,300 | ||||
Unaudited Reconciliation of GAAP Net Loss to Non-GAAP EBITDA
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| (in thousands) | ||||||||||||||||
| Net loss (GAAP) | $ | (11,252 | ) | $ | (6,434 | ) | $ | (32,645 | ) | $ | (18,761 | ) | ||||
| Depreciation and amortization expense | 1,081 | 743 | 3,069 | 1,778 | ||||||||||||
| Interest income | (2,701 | ) | (1,394 | ) | (7,558 | ) | (1,965 | ) | ||||||||
| Income taxes | — | — | — | — | ||||||||||||
| EBITDA (Non-GAAP) | $ | (12,871 | ) | $ | (7,085 | ) | $ | (37,134 | ) | $ | (18,948 | ) | ||||
